Controlling epileptic seizures during gestation represents one of the most delicate balancing acts in modern obstetric neurology. Maintaining continuous therapy prevents life-threatening status epilepticus, maternal hypoxia, and fetal distress. However, clinicians must also weigh how fetal drug contact alters delicate cerebral maturation. Investigating the nuances of prenatal antiseizure medication exposure has therefore become a pivotal priority for maternal-fetal medicine and pediatric neurology alike.

Investigating Prenatal Antiseizure Medication Exposure Across Monotherapies

To address lingering questions regarding newer and older antiseizure medications (ASMs), researchers evaluated a semiprospective cohort from the Raoul Wallenberg Australian Pregnancy Register of Antiepileptic Drugs. The investigators followed 110 children between the ages of 3 and 18 years from birth onward. Importantly, all included children lacked major congenital structural malformations, allowing researchers to isolate distinct cognitive phenotypes. Ninety-one children experienced in utero exposure to monotherapy regimens of carbamazepine, lamotrigine, levetiracetam, valproate, or topiramate, while 19 unexposed children born to women without active ASM treatment served as controls.

A blinded neuropsychologist administered comprehensive, standardized neuropsychological batteries, including the Wechsler Intelligence Scales. The investigators established Full-Scale IQ (FSIQ) and primary cognitive index scores as primary endpoints. Additionally, secondary evaluations thoroughly examined memory, language, academic achievement, and executive functions. Generalized linear mixed-effects models estimated associations between drug exposures and neurocognitive performance, adjusting for maternal intelligence quotient, epilepsy features, and critical perinatal confounders.

Differential Impacts on Cognitive Domains and Full-Scale IQ

The study yielded Class II evidence demonstrating marked differences across specific antiseizure monotherapies. Children with prenatal antiseizure medication exposure involving topiramate, levetiracetam, valproate, or carbamazepine demonstrated significantly reduced scores across multiple neurocognitive metrics compared with unexposed controls. These reductions appeared prominent across processing speed, verbal comprehension, visuospatial reasoning, and standardized academic skills, showing substantial effect sizes with Cohen d values ranging between -0.8 and -1.0.

Remarkably, the largest deficits in Full-Scale IQ emerged among children exposed prenatally to topiramate (mean difference: -17.4 points) and levetiracetam (mean difference: -13.9 points). Although valproate historically demonstrates the most severe teratogenic profile in neurodevelopmental literature, its observed effect in this cohort appeared somewhat attenuated, likely reflecting modern clinical practices that minimize prescribed dosages. Furthermore, cognitive disparities did not correlate significantly with maternal drug dosage, though smaller subgroup sample sizes might have limited statistical power to detect subtle dose-dependent gradients.

Contrasting Drug Profiles: Lamotrigine Demonstrates Relative Neurodevelopmental Safety

In striking contrast to other assessed agents, lamotrigine-exposed children displayed intellectual and academic performance completely comparable to unexposed peers. Across intelligence indices, memory assessments, and executive functioning tests, offspring exposed to lamotrigine in utero maintained normative scores. Consequently, these findings reinforce growing international evidence that identifies lamotrigine as one of the least neurotoxic options during embryogenesis and fetal brain maturation.

Conversely, the pronounced cognitive decrement observed with levetiracetam was unexpected given previous observational literature suggesting general safety. However, domain-specific vulnerabilities, particularly in processing speed and working memory, align with emerging registry data indicating subtle behavioral and executive hurdles. Similarly, topiramate demonstrated robust negative associations with academic achievement and global intelligence, corroborating prior warnings regarding its anti-folate mechanism and neurodevelopmental hazards.

Clinical Implications for Epilepsy Management During Pregnancy

These findings carry profound implications for healthcare providers advising female patients of reproductive potential. Because abrupt cessation of antiseizure medication introduces extreme maternal and fetal mortality risks, physicians must avoid reactive, unmonitored drug discontinuation during pregnancy. Instead, clinicians should conduct pre-pregnancy counseling to carefully evaluate whether a woman can transition safely to a regimen with lower neurodevelopmental risk, such as lamotrigine monotherapy, before conception occurs.

When clinicians manage patients who require topiramate, valproate, or carbamazepine for refractory seizure control, they must offer comprehensive counseling regarding potential cognitive vulnerabilities. Moreover, pediatricians and family physicians should monitor children with prenatal antiseizure medication exposure closely throughout their schooling years. Identifying early difficulties in verbal comprehension, visual processing, and academic skills enables timely educational interventions, speech therapy, and neuropsychological support.

Optimizing Treatment Protocols and Future Research Horizons

Ultimately, clinical care must prioritize individualized therapeutic drug monitoring across all trimesters. Physiological changes during pregnancy dramatically increase plasma clearance for several ASMs, especially lamotrigine and levetiracetam. Therefore, practitioners should monitor serum drug concentrations regularly to maintain minimum effective therapeutic levels, preventing breakthrough maternal seizures while avoiding unnecessary fetal overexposure.

Future prospective investigations must expand upon these findings by tracking larger multinational cohorts into late adolescence and adulthood. Clarifying the interplay between genetic susceptibility, gestational timing of exposure, and folate metabolism will refine risk stratification. For now, multidisciplinary collaboration among neurologists, obstetricians, and pediatricians remains paramount to ensuring optimal maternal seizure control alongside healthy long-term neurocognitive trajectories for the next generation.

Frequently Asked Questions

How does prenatal exposure to lamotrigine compare to other antiseizure drugs?

Lamotrigine demonstrates a favorable neurodevelopmental safety profile during pregnancy. Research shows that children exposed to lamotrigine monotherapy achieve Full-Scale IQ scores, executive functions, and academic performance comparable to unexposed children. Consequently, clinicians frequently consider lamotrigine a preferred first-line option for women with epilepsy planning a pregnancy.

Why did levetiracetam show cognitive vulnerabilities in this Australian cohort?

In this cohort, levetiracetam was unexpectedly associated with lower Full-Scale IQ and processing speed scores. While several previous studies suggested excellent neurodevelopmental safety for levetiracetam, this detailed neuropsychological assessment highlights domain-specific vulnerabilities. Further large-scale longitudinal investigations are essential to clarify whether dosage or specific gestational timing influenced these results.

Should pregnant women with epilepsy stop their antiseizure medication?

Pregnant women must not discontinue their antiseizure medication without specialist guidance. Uncontrolled generalized tonic-clonic seizures pose severe risks to both the mother and fetus, including hypoxemia, trauma, and miscarriage. Clinicians should evaluate risks and benefits carefully, switching to safer agents like lamotrigine well before conception whenever clinically feasible.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should exercise their clinical judgment and refer to the latest local and national guidelines for clinical practice.

References

1. Honybun E et al. Neurocognitive Outcomes of In Utero Exposure to Antiseizure Medication: An Australian Cohort Study. Neurology. 2026 Jul 14. doi: 10.1212/WNL.0000000000218122. PMID: 42247656.


2. Meador KJ et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244-252.


3. Tomson T et al. Comparative risk of major congenital malformations and neurodevelopmental outcomes with antiepileptic drugs in pregnancy: a guideline from the American Epilepsy Society and the American Academy of Neurology. Neurology. 2024;102(9):e209355.